Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects
Status:
Withdrawn
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the bioequivalence of the test product, Exemestane
25 mg tablets of Actavis Group PTC ehf. Iceland, and the reference product, Aromasin®
(exemestane) 25 mg tablets of Pharmacia & Upjohn Company, Division of Pfizer Inc., New York,
United States of America in healthy male and postmenopausal female subjects, under fasting
conditions